Glenmark Pharmaceuticals Limited has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which…
eTurboNews raksti ir paredzēti tikai abonentiem. Abonements ir BEZMAKSAS.
Abonenti piesakās šeit Noklikšķiniet šeit, lai abonētu BEZMAKSAS
Abonenti piesakās šeit Noklikšķiniet šeit, lai abonētu BEZMAKSAS
KAS IZŅEMT NO ŠĪ RAKSTA:
- This is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled Type 2 diabetes.
- Glenmark Pharmaceuticals Limited has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone.
- Glenmark has launched this FDC under the brand name Zita Plus Pio, which….
